LAUSR

Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients

Sign Up to like & get
recommendations!
1 Published in 2022 at "Cancers"

DOI: 10.3390/cancers14051290

Abstract: Simple Summary Trabectedin is an FDA-approved chemotherapy with demonstrated benefit for some sarcoma subtypes, particularly in the metastatic setting. Although some patients receiving trabectedin have only modest benefit, other patients are exceptional responders. While several… read more here.

Keywords: analysis; expression; immunologic gene; gene ... See more keywords